SCHEMBL5368918

SCHEMBL5368918

CCOC(=O)c1c(C)[nH]c(C=C2C(=O)Nc3ccc(Br)c(C)c32)c1C

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 7/20 0.66
FGFR1 P11362 4/20 0.66
ALK Q9UM73 2/20 0.66
RET P07949 2/20 0.66
FLT3 P36888 2/20 0.66
ABL1 P00519 1/20 0.66
CSF1R P07333 2/20 0.47
KDR P35968 8/20 0.46
EGFR P00533 2/20 0.46
PDGFRA P16234 1/20 0.46
PRKAA1 Q13131 6/20 0.44
PRKAA2 P54646 4/20 0.44
TLK2 Q86UE8 1/20 0.44
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
MAPT P10636 1/20 0.43
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HDAC3 O15379 1/20 0.42
HDAC4 P56524 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7136788 0.83 PDGFRB (0.58) PDGFRBFGFR1ALKRETFLT3
SCHEMBL5392303 0.82 PDGFRB (0.74) PDGFRBFGFR1ALKRETFLT3
SCHEMBL5358202 0.82 PDGFRB (0.45) PDGFRBFGFR1ALKRETFLT3
SCHEMBL5367053 0.80 PDGFRB (0.50) PDGFRBFGFR1ALKRETFLT3
SCHEMBL19255670 0.80 PDGFRB (0.77) PDGFRBFGFR1ALKRETFLT3
SCHEMBL6001446 0.80 FGFR1 (1.00) PDGFRBFGFR1ALKRETFLT3
SCHEMBL378979 0.80 FGFR1 (1.00) PDGFRBFGFR1ALKRETFLT3
SCHEMBL5390359 0.80 FGFR1 (1.00) PDGFRBFGFR1ALKRETFLT3
SCHEMBL5373629 0.79 PDGFRB (0.76) PDGFRBFGFR1ALKRETFLT3
SCHEMBL5376617 0.78 PDGFRB (0.74) PDGFRBFGFR1ALKRETFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK PDGFRB 52/4885FGFR1 112/4885ALK 325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.